flecainide has been researched along with Tachycardia in 154 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In our report, we describe a case of TC in a 30-years old female with a medical history of episodes of focal atrial tachycardia (AT) after intravenous administration of a single, maximum dose of flecainide." | 8.12 | Takotsubo cardiomyopathy triggered by a single dose of flecainide in patient with focal atrial tachycardia. ( Cygański, P; Konsek-Komorowska, SJ; Rynkiewicz, A, 2022) |
| "Flecainide pill-in-the-pocket therapy is a pharmacologic treatment option for patients with infrequent episodes of symptomatic atrial fibrillation." | 7.96 | Paroxysmal Atrial Fibrillation on Flecainide Therapy. ( Gavin, JL; Kim, SS; Peigh, GS, 2020) |
| "Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise." | 7.76 | Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. ( Gandhi, MM; Lloyd, G; Taylor, R, 2010) |
| "An infant with intrauterine supraventricular tachycardia and fetal hydrops, successfully treated with administration of flecainide acetate to the mother had conjugated hyperbilirubinemia shortly after birth." | 7.69 | Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. ( Carlson, DE; Cocjin, J; Rosenthal, P; Santulli, TV; Vanderhal, AL, 1995) |
| "Efficacy of flecainide was investigated in 50 patients with sustained ventricular tachycardia (n = 38) or ventricular fibrillation (n = 12) during a 4-week in-hospital and 1-year follow-up period." | 7.68 | Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. ( Crijns, HJ; Kingma, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM; Wesseling, H, 1990) |
| "A combination of oral flecainide and mexiletine was given to 11 patients in whom monotherapy with one of these drugs was ineffective for the suppression of inducible ventricular tachycardia or fibrillation." | 7.68 | Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias. ( Clement, DL; Jordaens, LJ; Robbens, E; Tavernier, R; Vanmeerhaeghe, X, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 7.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "Fourteen mothers were treated with flecainide for fetal atrial tachycardias associated with intrauterine cardiac failure." | 7.68 | Flecainide in the treatment of fetal tachycardias. ( Allan, LD; Chita, SK; Maxwell, D; Priestley, K; Sharland, GK, 1991) |
| " Programmed electrical stimulation using up to three closely coupled premature stimuli and burst pacing was used to test the inducibility of arrhythmias both during control and administration of 1 micrograms/ml flecainide." | 7.68 | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. ( Allessie, M; Boersma, L; Brugada, J; Kirchhof, C, 1991) |
| "Flecainide, a Class IC antiarrhythmic agent, was used in 12 patients with an average age of 57 years to treat spontaneous monomorphic sustained ventricular tachycardia (S-VT, n = 9), with a ventricular rhythm of 203 +/- 41 bpm (5 right bundle branch and 4 left bundle branch block pattern) and non-sustained ventricular tachycardia (NS-VT, n = 3)." | 7.68 | [Estimation of the long-term efficacy of anti-arrhythmia treatment with flecainide in ventricular tachycardia]. ( Babuty, B; Cosnay, P; Estepo, J; Fauchier, JP; Moquet, B; Rouesnel, P, 1990) |
| "Two infants with chaotic atrial tachycardia diagnosed at birth and at 11 weeks of life, were treated successfully with oral flecainide." | 7.68 | Successful treatment of chaotic atrial tachycardia with oral flecainide. ( Davignon, A; Fournier, A; Houyel, L, 1990) |
| "To assess the efficacy of encainide and flecainide in treating patients with sustained ventricular arrhythmias." | 7.68 | Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. ( Eldar, M; Franz, MR; Griffin, JC; Herre, JM; Oeff, M; Scheinman, MM; Titus, C, 1990) |
| " We observed the appearance of ventricular tachycardia with an unusual sinusoidal QRS complex in three of five such patients treated with flecainide acetate, 200 mg twice daily." | 7.67 | Sinusoidal ventricular tachycardia associated with flecainide acetate. ( DiMarco, JP; Sellers, TD, 1984) |
| "In a heterogeneous group of 15 patients with clinical syncope or documented sustained ventricular tachycardia (VT), with induced sustained or nonsustained VT at programmed electrical stimulation, flecainide prevented tachycardia induction in 9 of 15 patients (60%) and improved responses in 2, for a 73% initial favorable response rate." | 7.67 | Experience with electrophysiologically guided therapy of ventricular tachycardia with flecainide: summary of long-term follow-up. ( Anderson, JL, 1984) |
| "The efficacy and safety of oral flecainide for treatment of ventricular arrhythmias were assessed during a 3-day period in patients with various cardiac diseases." | 7.67 | Oral flecainide for suppression of ventricular arrhythmias. ( Balakumaran, K; Hugenholtz, PG; Lubsen, J; Roelandt, J; Vanhaleweyk, G, 1984) |
| "Drug efficacy and pharmacokinetics were assessed in 63 patients, aged 5 days to 30 years (mean 8 years), who received flecainide acetate for control of resistant arrhythmias." | 7.67 | Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ( Fredell, P; Garson, A; Gothing, C; McQuinn, RL; Perry, JC; Smith, RT, 1989) |
| "Flecainide acetate has a recognized proarrhythmic effect in patients treated for ventricular tachycardia." | 7.67 | Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. ( Falk, RH, 1989) |
| "The antiarrhythmic activity of flecainide has been tested in seven old patients (mean age 71 years) suffering from recurrent episodes of ventricular tachycardia." | 7.67 | [Efficacy of flecainide in the treatment of ventricular tachycardia in the elderly. Dynamic electrocardiographic study]. ( Attanasio, A; Capria, A; Fabrizi, E; Filice, A; Piccolo, CG, 1989) |
| "Thirty-nine patients with symptomatic ectopic atrial tachycardia (9 paroxysmal, of which 5 were incessant) and atrial fibrillation (AF) (25 paroxysmal, 5 chronic) were treated with oral flecainide acetate (100 to 400 mg/day)." | 7.67 | Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. ( Berns, E; Dougherty, AH; Jeang, MK; Jenkins, M; Naccarelli, GV; Rinkenberger, RL, 1987) |
| "A 69-year-old man had new sustained ventricular tachycardia caused by flecainide which promptly responded to intravenous lidocaine therapy." | 7.67 | Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine. ( Bauman, JL; Gallastegui, J; Hariman, RJ; Tanenbaum, SR, 1987) |
| "The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction." | 7.67 | Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. ( DiCarlo, LA; Lucchesi, BR; Lynch, JJ; Montgomery, DG, 1987) |
| "Fifty-one consecutive patients with atrial tachycardia [atrial fibrillation (FA) 37, atrial flutter (Fl) 10, tachycardia (TSA) 4] received a single 2 mg/kg dose of flecainide injected intravenously over 5 to 10 minutes." | 7.67 | [Reduction of auricular fibrillation and tachycardia using intravenous flecainide]. ( Aumont, MC; Boujon, B; Charlier, P; Cohen-Solal, A; Dahan, M; Farinotti, P; Jaeger, P; Juliard, JM, 1987) |
| "The electrophysiologic effects and antiarrhythmic efficacy of flecainide were evaluated by electrophysiologic study (EPS) in 20 patients with ventricular tachycardia (VT) refractory to an average 2." | 7.67 | Clinical and electrophysiologic effects of flecainide in patients with refractory ventricular tachycardia. ( Capparelli, EV; Chow, MS; Kluger, J; Regnier, JC, 1988) |
| "A 42-year old man with non-obstructive myocardiopathy complicated by paroxysmal atrial fibrillation treated with amiodarone (200 mg per day) received flecainide in daily doses of 400 mg for undocumented palpitations." | 7.67 | [Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect]. ( Berland, J; Cribier, A; Letac, B; Saoudi, N, 1988) |
| "Ninety-four patients with ventricular tachycardia (VT), 49 with sustained and 45 with nonsustained VT, who had been refractory to or intolerant of other antiarrhythmic agents were treated in a multicenter, open-label study with flecainide acetate." | 7.67 | Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group. ( , 1986) |
| "A 32-year-old woman with prolapsed mitral valve was treated with flecainide because of an episode of primary ventricular fibrillation." | 7.67 | Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity. ( Follath, F; Hoffmann, A; Wenk, M, 1986) |
| "Thirty-two patients received flecainide acetate for nonsustained ventricular tachycardia after having had unsuccessful treatment with a mean of four antiarrhythmic drugs." | 7.67 | Flecainide in the treatment of nonsustained ventricular tachycardia. ( Chapman, PD; Dougherty, AH; Kim, SS; Lal, R; Naccarelli, GV; Rinkenberger, RL; Ruffy, R; Schechtman, KB; Troup, PJ, 1986) |
| "The effect of flecainide acetate, a class 1c antiarrhythmic agent, was examined in 15 patients with recurrent ventricular tachycardia." | 7.67 | Effect of intravenous and oral flecainide on ventricular tachycardia. ( Cheesman, M; Dancy, M; Ward, DE, 1986) |
| "The response of sustained supraventricular tachycardia to intravenous and oral flecainide acetate was investigated in 5 children, aged 5." | 7.67 | Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. ( Jones, S; Shinebourne, EA; Ward, DE, 1986) |
| "Intravenous flecainide successfully terminated atrial tachycardia in three patients." | 7.67 | Successful treatment of atrial tachycardias with flecainide acetate. ( Camm, AJ; Creamer, JE; Nathan, AW, 1985) |
| "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 +/- 87 mg [mean +/- standard deviation])." | 7.67 | Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. ( Estes, M; Garan, H; Griffith, LS; Heine, DL; Platia, EV; Reid, PR; Ruskin, JN, 1985) |
| "Four patients with recurrent, symptomatic ventricular tachycardia (VT) refractory to conventional antiarrhythmic agents were given flecainide acetate to control arrhythmias." | 7.66 | Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. ( Abt, ME; Goldstein, RE; Oetgen, WJ; Tibbits, PA, 1983) |
| "Flecainide was more effective than quinidine in suppressing chronic ventricular arrhythmias (especially complex forms), and thus is an important new antiarrhythmic agent." | 6.65 | Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. ( , 1983) |
| " Flecainide appeared to be safe (no deaths with usual oral dosing, < 1% serious proarrhythmia) and effective (73% to 100% control, depending on mechanism) in children with supraventricular tachycardia." | 6.38 | Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. ( Garson, A; Perry, JC, 1992) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 5.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| "Flecainide acetate is a new class I antiarrhythmic agent which slows atrial, A-V nodal and ventricular conduction velocity, and prolongs refractoriness of these structures (Borchard et al." | 5.27 | Flecainide-induced aggravation of ventricular tachycardia. ( Hohnloser, S; Hust, MH; Just, H; Wollschläger, H; Zeiher, A, 1983) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 5.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| "Moricizine was studied in 908 patients with ventricular arrhythmias." | 5.06 | Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis. ( Pratt, CM, 1990) |
| "The relative safety and efficacy of intravenous administration of adenosine, lignocaine, disopyramide, flecainide, and sotalol for termination of stable, induced ventricular tachycardia was assessed in serial trials." | 5.06 | Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. ( Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990) |
| "We performed a systematic review and meta-analysis to compare digoxin, flecainide, or sotalol as first-line therapy for fetal tachycardia." | 4.95 | Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. ( Frommelt, MA; Hill, GD; Kovach, JR; Saudek, DE; Singh, AK; Wehrheim, K, 2017) |
| "The use of flecainide and propafenone for medical cardioversion of atrial fibrillation (AF) and atrial flutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD)." | 4.31 | Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. ( Alexander, ME; Bezzerides, VJ; DeWitt, ES; Dionne, A; Eberly, LM; Mah, DY; O'Leary, ET; Przybylski, R; Triedman, JK; Walsh, EP, 2023) |
| "High-dose flecainide and digoxin combination offers effective treatment strategy in fetuses with hydrops and tachyarrhythmia with favourable outcomes." | 4.12 | Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review. ( Beattie, RB; Tunca Sahin, G; Uzun, O, 2022) |
| " In our report, we describe a case of TC in a 30-years old female with a medical history of episodes of focal atrial tachycardia (AT) after intravenous administration of a single, maximum dose of flecainide." | 4.12 | Takotsubo cardiomyopathy triggered by a single dose of flecainide in patient with focal atrial tachycardia. ( Cygański, P; Konsek-Komorowska, SJ; Rynkiewicz, A, 2022) |
| "Flecainide pill-in-the-pocket therapy is a pharmacologic treatment option for patients with infrequent episodes of symptomatic atrial fibrillation." | 3.96 | Paroxysmal Atrial Fibrillation on Flecainide Therapy. ( Gavin, JL; Kim, SS; Peigh, GS, 2020) |
| "A patient taking regular flecainide for paroxysmal atrial fibrillation presented with broad complex tachycardia and circulatory compromise." | 3.81 | Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination. ( Apps, A; Fellows, S; Jones, M; Miller, CP, 2015) |
| "Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise." | 3.76 | Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. ( Gandhi, MM; Lloyd, G; Taylor, R, 2010) |
| "Magnesium sulphate was added to conventional medical therapy in the treatment of persistent severe hypotension and wide QRS complex tachyarrhythmia in an 18-year-old woman presenting with a 1200 mg flecainide overdose." | 3.76 | Management of persistent wide QRS in flecainide overdose with magnesium sulphate. ( Frost, I; Singh, VK; Sinha, A; Williamson, DG, 2010) |
| "A 2-year-old male with a history of a persistent junctional reciprocating tachycardia had been receiving flecainide 4." | 3.75 | Life-threatening flecainide intoxication in a young child secondary to medication error. ( Buffo-Sequiera, I; D'Alessandro, LC; Freeman, D; Gloor, J; Rieder, MJ, 2009) |
| "The basis of the unique effectiveness of amiodarone for atrial fibrillation (AF) is poorly understood." | 3.72 | Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. ( Nattel, S; Schram, G; Shinagawa, K; Shiroshita-Takeshita, A, 2003) |
| "We discovered supraventricular tachycardia with advanced hydrops in the setting of normal cardiac anatomy at 26 weeks of gestation which resolved successfully following administration of digoxin and flecainide to the mother." | 3.70 | Fetal hydrops due to a tachyarrhythmia progressing to organic pulmonary stenosis. ( Fesslova, V; Nicolini, U; Villa, L, 2000) |
| "An infant with intrauterine supraventricular tachycardia and fetal hydrops, successfully treated with administration of flecainide acetate to the mother had conjugated hyperbilirubinemia shortly after birth." | 3.69 | Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops. ( Carlson, DE; Cocjin, J; Rosenthal, P; Santulli, TV; Vanderhal, AL, 1995) |
| " In patients refractory to amiodarone alone or to a combination with mexiletine, the combined treatment with amiodarone and class-I-C drugs such as flecainide and encainide prolongs the cycle length of ventricular tachycardia, but does not suppress induction of ventricular tachycardia during programmed stimulation." | 3.68 | [Combination anti-arrhythmic drug therapy]. ( Jung, W; Lüderitz, B; Manz, M, 1992) |
| "Efficacy of flecainide was investigated in 50 patients with sustained ventricular tachycardia (n = 38) or ventricular fibrillation (n = 12) during a 4-week in-hospital and 1-year follow-up period." | 3.68 | Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation. ( Crijns, HJ; Kingma, HJ; Lie, KI; van Gelder, IC; van Gilst, WH; van Wijk, LM; Wesseling, H, 1990) |
| "A combination of oral flecainide and mexiletine was given to 11 patients in whom monotherapy with one of these drugs was ineffective for the suppression of inducible ventricular tachycardia or fibrillation." | 3.68 | Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias. ( Clement, DL; Jordaens, LJ; Robbens, E; Tavernier, R; Vanmeerhaeghe, X, 1990) |
| " The class Ic steroidal antiarrhythmic agent, Org 7797, was compared with two other Ic agents, flecainide and propafenone for intravenous activity against ischaemia-related cardiac arrhythmias and for electrophysiological actions in vivo." | 3.68 | Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs. ( Barron, E; Campbell, JK; Marshall, RJ; Muir, AW; Winslow, E, 1991) |
| "Fourteen mothers were treated with flecainide for fetal atrial tachycardias associated with intrauterine cardiac failure." | 3.68 | Flecainide in the treatment of fetal tachycardias. ( Allan, LD; Chita, SK; Maxwell, D; Priestley, K; Sharland, GK, 1991) |
| " Programmed electrical stimulation using up to three closely coupled premature stimuli and burst pacing was used to test the inducibility of arrhythmias both during control and administration of 1 micrograms/ml flecainide." | 3.68 | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. ( Allessie, M; Boersma, L; Brugada, J; Kirchhof, C, 1991) |
| "Flecainide, a Class IC antiarrhythmic agent, was used in 12 patients with an average age of 57 years to treat spontaneous monomorphic sustained ventricular tachycardia (S-VT, n = 9), with a ventricular rhythm of 203 +/- 41 bpm (5 right bundle branch and 4 left bundle branch block pattern) and non-sustained ventricular tachycardia (NS-VT, n = 3)." | 3.68 | [Estimation of the long-term efficacy of anti-arrhythmia treatment with flecainide in ventricular tachycardia]. ( Babuty, B; Cosnay, P; Estepo, J; Fauchier, JP; Moquet, B; Rouesnel, P, 1990) |
| "Two infants with chaotic atrial tachycardia diagnosed at birth and at 11 weeks of life, were treated successfully with oral flecainide." | 3.68 | Successful treatment of chaotic atrial tachycardia with oral flecainide. ( Davignon, A; Fournier, A; Houyel, L, 1990) |
| "To assess the efficacy of encainide and flecainide in treating patients with sustained ventricular arrhythmias." | 3.68 | Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. ( Eldar, M; Franz, MR; Griffin, JC; Herre, JM; Oeff, M; Scheinman, MM; Titus, C, 1990) |
| " We observed the appearance of ventricular tachycardia with an unusual sinusoidal QRS complex in three of five such patients treated with flecainide acetate, 200 mg twice daily." | 3.67 | Sinusoidal ventricular tachycardia associated with flecainide acetate. ( DiMarco, JP; Sellers, TD, 1984) |
| "In a heterogeneous group of 15 patients with clinical syncope or documented sustained ventricular tachycardia (VT), with induced sustained or nonsustained VT at programmed electrical stimulation, flecainide prevented tachycardia induction in 9 of 15 patients (60%) and improved responses in 2, for a 73% initial favorable response rate." | 3.67 | Experience with electrophysiologically guided therapy of ventricular tachycardia with flecainide: summary of long-term follow-up. ( Anderson, JL, 1984) |
| "Flecainide has unusual electrophysiologic properties and a high potency for the suppression of ventricular tachyarrhythmias." | 3.67 | Effects of flecainide on ventricular function: clinical and experimental correlations. ( Ikeda, N; Josephson, MA; Singh, BN, 1984) |
| "The efficacy and safety of oral flecainide for treatment of ventricular arrhythmias were assessed during a 3-day period in patients with various cardiac diseases." | 3.67 | Oral flecainide for suppression of ventricular arrhythmias. ( Balakumaran, K; Hugenholtz, PG; Lubsen, J; Roelandt, J; Vanhaleweyk, G, 1984) |
| "Drug efficacy and pharmacokinetics were assessed in 63 patients, aged 5 days to 30 years (mean 8 years), who received flecainide acetate for control of resistant arrhythmias." | 3.67 | Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ( Fredell, P; Garson, A; Gothing, C; McQuinn, RL; Perry, JC; Smith, RT, 1989) |
| "Flecainide acetate has a recognized proarrhythmic effect in patients treated for ventricular tachycardia." | 3.67 | Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. ( Falk, RH, 1989) |
| "Flecainide toxicity occurred in an infant being treated for refractory atrioventricular re-entry tachycardia." | 3.67 | Flecainide toxicity. ( Martin, RP; Russell, GA, 1989) |
| "The antiarrhythmic activity of flecainide has been tested in seven old patients (mean age 71 years) suffering from recurrent episodes of ventricular tachycardia." | 3.67 | [Efficacy of flecainide in the treatment of ventricular tachycardia in the elderly. Dynamic electrocardiographic study]. ( Attanasio, A; Capria, A; Fabrizi, E; Filice, A; Piccolo, CG, 1989) |
| "Seventy-six patients with ventricular tachyarrhythmias (40 sustained and 36 nonsustained) were treated with oral flecainide." | 3.67 | Influence of left ventricular dysfunction on flecainide therapy. ( de Paola, AA; Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Senior, S; Spielman, SR, 1987) |
| "Definitions of proarrhythmia, including clinical consequence, were applied to the flecainide and encainide data bases to determine risk factors for serious proarrhythmic events or deaths." | 3.67 | Risk factors for the development of proarrhythmic events. ( Morganroth, J, 1987) |
| "Ventricular tachyarrhythmias and severe bradycardia, flecainide acetate's most serious side effects, occur in patients with chronic heart disease or in healthy persons after frank overdose." | 3.67 | Life-threatening flecainide toxicity. A pharmacodynamic approach. ( Leinberger, H; Winkelmann, BR, 1987) |
| "Thirty-nine patients with symptomatic ectopic atrial tachycardia (9 paroxysmal, of which 5 were incessant) and atrial fibrillation (AF) (25 paroxysmal, 5 chronic) were treated with oral flecainide acetate (100 to 400 mg/day)." | 3.67 | Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. ( Berns, E; Dougherty, AH; Jeang, MK; Jenkins, M; Naccarelli, GV; Rinkenberger, RL, 1987) |
| "A 69-year-old man had new sustained ventricular tachycardia caused by flecainide which promptly responded to intravenous lidocaine therapy." | 3.67 | Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine. ( Bauman, JL; Gallastegui, J; Hariman, RJ; Tanenbaum, SR, 1987) |
| "The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction." | 3.67 | Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. ( DiCarlo, LA; Lucchesi, BR; Lynch, JJ; Montgomery, DG, 1987) |
| "Fifty-one consecutive patients with atrial tachycardia [atrial fibrillation (FA) 37, atrial flutter (Fl) 10, tachycardia (TSA) 4] received a single 2 mg/kg dose of flecainide injected intravenously over 5 to 10 minutes." | 3.67 | [Reduction of auricular fibrillation and tachycardia using intravenous flecainide]. ( Aumont, MC; Boujon, B; Charlier, P; Cohen-Solal, A; Dahan, M; Farinotti, P; Jaeger, P; Juliard, JM, 1987) |
| "The electrophysiologic effects and antiarrhythmic efficacy of flecainide were evaluated by electrophysiologic study (EPS) in 20 patients with ventricular tachycardia (VT) refractory to an average 2." | 3.67 | Clinical and electrophysiologic effects of flecainide in patients with refractory ventricular tachycardia. ( Capparelli, EV; Chow, MS; Kluger, J; Regnier, JC, 1988) |
| "A 42-year old man with non-obstructive myocardiopathy complicated by paroxysmal atrial fibrillation treated with amiodarone (200 mg per day) received flecainide in daily doses of 400 mg for undocumented palpitations." | 3.67 | [Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect]. ( Berland, J; Cribier, A; Letac, B; Saoudi, N, 1988) |
| "Ninety-four patients with ventricular tachycardia (VT), 49 with sustained and 45 with nonsustained VT, who had been refractory to or intolerant of other antiarrhythmic agents were treated in a multicenter, open-label study with flecainide acetate." | 3.67 | Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group. ( , 1986) |
| "A 32-year-old woman with prolapsed mitral valve was treated with flecainide because of an episode of primary ventricular fibrillation." | 3.67 | Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity. ( Follath, F; Hoffmann, A; Wenk, M, 1986) |
| "Thirty-two patients received flecainide acetate for nonsustained ventricular tachycardia after having had unsuccessful treatment with a mean of four antiarrhythmic drugs." | 3.67 | Flecainide in the treatment of nonsustained ventricular tachycardia. ( Chapman, PD; Dougherty, AH; Kim, SS; Lal, R; Naccarelli, GV; Rinkenberger, RL; Ruffy, R; Schechtman, KB; Troup, PJ, 1986) |
| " Antiarrhythmic effects of flecainide and its enantiomers were assessed in two different animal models, chloroform-induced ventricular fibrillation in mice and ouabain-induced ventricular tachycardia in dogs." | 3.67 | Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers. ( Banitt, EH; Newmark, RA; Schmid, JR, 1986) |
| "The effect of flecainide acetate, a class 1c antiarrhythmic agent, was examined in 15 patients with recurrent ventricular tachycardia." | 3.67 | Effect of intravenous and oral flecainide on ventricular tachycardia. ( Cheesman, M; Dancy, M; Ward, DE, 1986) |
| "The response of sustained supraventricular tachycardia to intravenous and oral flecainide acetate was investigated in 5 children, aged 5." | 3.67 | Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. ( Jones, S; Shinebourne, EA; Ward, DE, 1986) |
| "Flecainide was initially prescribed at a dose of 200 mg twice daily, but after early toxicity in patients with ventricular tachycardia (VT), the dosage was reduced to 100 mg twice daily." | 3.67 | Flecainide: long-term treatment using a reduced dosing schedule. ( Flowers, D; Miura, D; O'Gallagher, D; Somberg, JC; Torres, V, 1985) |
| "Intravenous flecainide successfully terminated atrial tachycardia in three patients." | 3.67 | Successful treatment of atrial tachycardias with flecainide acetate. ( Camm, AJ; Creamer, JE; Nathan, AW, 1985) |
| "Twenty-two patients with coronary artery disease and spontaneous ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent intracardiac electrophysiologic evaluation and, when possible, ambulatory monitoring before and after therapy with flecainide (mean dose 418 +/- 87 mg [mean +/- standard deviation])." | 3.67 | Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. ( Estes, M; Garan, H; Griffith, LS; Heine, DL; Platia, EV; Reid, PR; Ruskin, JN, 1985) |
| "Four patients with recurrent, symptomatic ventricular tachycardia (VT) refractory to conventional antiarrhythmic agents were given flecainide acetate to control arrhythmias." | 3.66 | Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. ( Abt, ME; Goldstein, RE; Oetgen, WJ; Tibbits, PA, 1983) |
| "Standardized treatment of fetal tachyarrhythmia has not been established." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy." | 2.82 | Arrhythmias in Pregnancy. ( Briller, JE; Elkayam, U; Lakkireddy, DR; Mason, PK; Merchant, FM; Patel, H; Pillarisetti, J; Russo, AM; Tamirisa, KP; Vaseghi, M; Volgman, AS, 2022) |
| "AFL accounts for 30% of fetal tachyarrhythmias, 11% to 18% of neonatal tachyarrhythmias, and 8% of supraventricular tachyarrhythmias in children older than 1 year of age." | 2.82 | Atrial Flutter in Pediatric Patients. ( Drago, F; Tamborrino, PP, 2022) |
| "There were 63 deaths/resuscitated cardiac arrests in the active treatment (encainide/flecainide) group and 26 in the placebo group." | 2.67 | Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Denes, P; Gillis, AM; Kammerling, JM; Pawitan, Y; Salerno, DM; Wilhelmsen, L, 1991) |
| "Flecainide was given in a dose of 200 mg twice daily." | 2.66 | Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions. ( Camm, AJ; Hellestrand, K; Muhiddin, KA; Turner, P, 1985) |
| "Flecainide was more effective than quinidine in suppressing chronic ventricular arrhythmias (especially complex forms), and thus is an important new antiarrhythmic agent." | 2.65 | Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial. ( , 1983) |
| " Flecainide appeared to be safe (no deaths with usual oral dosing, < 1% serious proarrhythmia) and effective (73% to 100% control, depending on mechanism) in children with supraventricular tachycardia." | 2.38 | Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. ( Garson, A; Perry, JC, 1992) |
| "Tachycardia is characterized by high beating rates that can lead to life-threatening fibrillations." | 1.72 | Functional evaluation of the tachycardia patient-derived iPSC cardiomyocytes carrying a novel pathogenic SCN5A variant. ( Akdeniz, C; Cagavi, E; Goktas Sahoglu, S; Kazci, YE; Torun, T; Tuncay, E; Tuzcu, V, 2022) |
| "Flecainide is a commonly used IC antiarrhythmic." | 1.72 | Wide complex tachycardia in dialysis patients is not always hyperkalemia. ( Hakmeh, W; Hoang, K; Pazderka, P, 2022) |
| "Tachycardia was finally controlled with flecainide while the patient was on left ventricular assist device support." | 1.33 | Successful treatment of tachycardia-induced cardiomyopathy with LVAD in a 12-year-old boy. ( Kaji, Y; Masuda, M; Morita, S; Nishida, T; Tatewaki, H; Ushinohama, H; Yasui, H, 2005) |
| "Flecainide acetate is a sodium channel blocker and a class Ic antiarrhythmic agent with potential life-threatening proarrhythmic and cardioinhibitory properties when taken in overdose." | 1.33 | Auto-intoxication with flecainide and quinapril: ECG-changes, symptoms and treatment. ( Dens, J; Van Reet, B, 2006) |
| "Syncope was abolished after successful radiofrequency catheter ablation of the AFL." | 1.31 | Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs. ( Azegami, K; Hiejima, K; Hirao, K; Horikawa, T; Kawabata, M; Motokawa, K; Suzuki, F; Suzuki, K, 2001) |
| "Tachycardia was observed in 15% of cases (three cases of supraventricular tachycardia [SVT] and two cases of auricular flutter [AF])." | 1.31 | [Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases]. ( Dubos, JP; Dufour, P; Puech, F; Subtil, D; Vaast, P; Vaksmann, G; Valat, AS; Vautier-Rit, S, 2000) |
| "Flecainide acetate has been shown to have use-dependent properties." | 1.29 | Use-dependent properties of flecainide acetate in accessory atrioventricular pathways. ( Goldberger, J; Helmy, I; Katzung, B; Scheinman, M, 1994) |
| " Daily flecainide dosage was 200 (100-400) mg." | 1.28 | Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients. ( Frandsen, F; Mickley, H; Møller, M; Pless, P, 1990) |
| " If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate." | 1.27 | New directions in antiarrhythmic drug therapy. ( Somberg, JC, 1984) |
| "For single ventricular extrasystoles, doublets and triplets, nine very good results (80 to 100 per cent reduction of arrhythmia) and four 50 to 80 per cent reductions in ventricular prematurity were obtained." | 1.27 | [Study of flecainide in the treatment of ventricular arrhythmia]. ( Errera, J; Hug, C; Koliopoulos, N; Puech, P; Tardy, C, 1983) |
| "Two patients who developed ventricular arrhythmias were taking other antiarrhythmic agents, and in this series proarrhythmic effects occurred with both normal and high flecainide concentrations." | 1.27 | Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. ( Banim, SO; Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW; Spurrell, RA, 1984) |
| "Flecainide acetate is a new class I antiarrhythmic agent which slows atrial, A-V nodal and ventricular conduction velocity, and prolongs refractoriness of these structures (Borchard et al." | 1.27 | Flecainide-induced aggravation of ventricular tachycardia. ( Hohnloser, S; Hust, MH; Just, H; Wollschläger, H; Zeiher, A, 1983) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 1.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| "Flecainide acetate was administered intravenously and orally to 12 consecutive children, aged 1-15 years, presenting with arrhythmias that were life threatening or resistant to conventional medical treatment." | 1.27 | The response of paediatric arrhythmias to intravenous and oral flecainide. ( Campbell, RW; Wren, C, 1987) |
| "Flecainide was evaluated in 93 patients, with 44 patients no longer having VT following flecainide (47% efficacy)." | 1.27 | Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide. ( Sacher, H; Schwarz, J; Somberg, JC; Tepper, D, 1987) |
| "His bundle tachycardia is a rare arrhythmia in infants and children and is resistant to therapy." | 1.27 | His bundle tachycardia--arrhythmogenic and antiarrhythmic effects of therapy. ( Campbell, RW; Wren, C, 1987) |
| "In cases of non-immune hydrops fetalis caused by tachyarrhythmias, the transplacental passage of antiarrhythmic drugs may be hampered." | 1.27 | Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs. ( Bald, R; Gembruch, U; Hansmann, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 76 (49.35) | 18.7374 |
| 1990's | 38 (24.68) | 18.2507 |
| 2000's | 14 (9.09) | 29.6817 |
| 2010's | 13 (8.44) | 24.3611 |
| 2020's | 13 (8.44) | 2.80 |
| Authors | Studies |
|---|---|
| Tunca Sahin, G | 1 |
| Beattie, RB | 1 |
| Uzun, O | 1 |
| Tamirisa, KP | 1 |
| Elkayam, U | 1 |
| Briller, JE | 1 |
| Mason, PK | 1 |
| Pillarisetti, J | 1 |
| Merchant, FM | 1 |
| Patel, H | 1 |
| Lakkireddy, DR | 1 |
| Russo, AM | 1 |
| Volgman, AS | 1 |
| Vaseghi, M | 1 |
| Konsek-Komorowska, SJ | 1 |
| Cygański, P | 1 |
| Rynkiewicz, A | 1 |
| Ünal Yüksekgönül, A | 1 |
| Azak, E | 1 |
| Akalın, A | 1 |
| Ertuğrul, İ | 1 |
| Kılıç, E | 1 |
| Utine, GE | 1 |
| Karagöz, T | 1 |
| Lopez Perales, CR | 1 |
| Fernandez Corredoira, PM | 1 |
| Chabbar Boudet, M | 1 |
| Goktas Sahoglu, S | 1 |
| Kazci, YE | 1 |
| Tuncay, E | 1 |
| Torun, T | 1 |
| Akdeniz, C | 1 |
| Tuzcu, V | 1 |
| Cagavi, E | 1 |
| Tsai, CF | 1 |
| Chuang, YT | 1 |
| Chang, KW | 1 |
| Drago, F | 1 |
| Tamborrino, PP | 1 |
| Kheiri, B | 1 |
| Vedantham, V | 1 |
| Scheinman, M | 2 |
| Przybylski, R | 1 |
| Eberly, LM | 1 |
| Alexander, ME | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Dionne, A | 1 |
| Mah, DY | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 1 |
| O'Leary, ET | 1 |
| Miyoshi, T | 1 |
| Maeno, Y | 1 |
| Hamasaki, T | 1 |
| Inamura, N | 1 |
| Yasukochi, S | 1 |
| Kawataki, M | 1 |
| Horigome, H | 1 |
| Yoda, H | 1 |
| Taketazu, M | 1 |
| Nii, M | 1 |
| Hagiwara, A | 1 |
| Kato, H | 1 |
| Shimizu, W | 1 |
| Shiraishi, I | 1 |
| Sakaguchi, H | 1 |
| Ueda, K | 1 |
| Katsuragi, S | 1 |
| Yamamoto, H | 1 |
| Sago, H | 1 |
| Ikeda, T | 1 |
| Sonesson, SE | 1 |
| Acharya, G | 1 |
| Gavin, JL | 1 |
| Peigh, GS | 1 |
| Kim, SS | 2 |
| Hoang, K | 1 |
| Pazderka, P | 1 |
| Hakmeh, W | 1 |
| Hill, GD | 1 |
| Kovach, JR | 1 |
| Saudek, DE | 1 |
| Singh, AK | 1 |
| Wehrheim, K | 1 |
| Frommelt, MA | 1 |
| Sakurai, K | 1 |
| Takahashi, K | 1 |
| Nakayashiro, M | 1 |
| Yamamoto, W | 1 |
| Hashimoto, N | 1 |
| Matsuura, J | 1 |
| Machida, T | 1 |
| Ogino, Y | 1 |
| Kobayashi, T | 1 |
| Yamanaka, Y | 1 |
| Ishiwata, N | 1 |
| Yamashita, T | 1 |
| Tanimoto, K | 1 |
| Miyoshi, S | 1 |
| Fukuda, K | 1 |
| Nakaya, H | 1 |
| Ogawa, S | 1 |
| Wang, W | 1 |
| Zhao, JJ | 1 |
| Wang, T | 1 |
| Wang, L | 1 |
| Jiang, XH | 1 |
| Doki, K | 2 |
| Sekiguchi, Y | 1 |
| Kuga, K | 2 |
| Aonuma, K | 1 |
| Homma, M | 2 |
| Apps, A | 1 |
| Miller, CP | 1 |
| Fellows, S | 1 |
| Jones, M | 1 |
| Napolitano, C | 1 |
| Hegde, S | 1 |
| Kumar, V | 1 |
| Van Hare, GF | 1 |
| Knapp, CF | 1 |
| Cooke, ER | 1 |
| Sheehan, DJ | 1 |
| D'Alessandro, LC | 1 |
| Rieder, MJ | 1 |
| Gloor, J | 1 |
| Freeman, D | 1 |
| Buffo-Sequiera, I | 1 |
| Taylor, R | 1 |
| Gandhi, MM | 1 |
| Lloyd, G | 1 |
| Williamson, DG | 1 |
| Sinha, A | 1 |
| Frost, I | 1 |
| Singh, VK | 1 |
| Wang, GS | 1 |
| Tham, E | 1 |
| Maes, J | 1 |
| Buchanan, JA | 1 |
| Shinagawa, K | 1 |
| Shiroshita-Takeshita, A | 1 |
| Schram, G | 1 |
| Nattel, S | 2 |
| Tsiperfal, A | 1 |
| Thompson, C | 1 |
| Katori, K | 1 |
| Yamaguchi, I | 1 |
| Sugibayashi, K | 1 |
| Kohda, Y | 1 |
| Ho, RT | 1 |
| DeCaro, M | 1 |
| Tatewaki, H | 1 |
| Masuda, M | 1 |
| Nishida, T | 1 |
| Kaji, Y | 1 |
| Ushinohama, H | 1 |
| Morita, S | 1 |
| Yasui, H | 1 |
| Gerli, S | 1 |
| Clerici, G | 1 |
| Mattei, A | 1 |
| Di Renzo, GC | 1 |
| Van Reet, B | 1 |
| Dens, J | 1 |
| Muhiddin, K | 1 |
| Nathan, AW | 5 |
| Hellestrand, KJ | 5 |
| Banim, SO | 3 |
| Camm, AJ | 10 |
| Somberg, JC | 6 |
| Hug, C | 1 |
| Koliopoulos, N | 1 |
| Tardy, C | 1 |
| Errera, J | 1 |
| Puech, P | 1 |
| Burnett, PJ | 1 |
| Milne, JR | 1 |
| Bexton, RS | 4 |
| Sellers, TD | 1 |
| DiMarco, JP | 1 |
| Orning, OM | 1 |
| Oetgen, WJ | 1 |
| Tibbits, PA | 1 |
| Abt, ME | 1 |
| Goldstein, RE | 1 |
| Spurrell, RA | 1 |
| Spivack, C | 1 |
| Gottlieb, S | 1 |
| Miura, DS | 1 |
| Reid, PR | 2 |
| Griffith, LS | 2 |
| Platia, EV | 2 |
| Ord, SE | 1 |
| Anderson, JL | 3 |
| Josephson, MA | 1 |
| Ikeda, N | 1 |
| Singh, BN | 1 |
| Vanhaleweyk, G | 1 |
| Balakumaran, K | 1 |
| Lubsen, J | 1 |
| Roelandt, J | 1 |
| Hugenholtz, PG | 1 |
| Hohnloser, S | 1 |
| Zeiher, A | 1 |
| Hust, MH | 1 |
| Wollschläger, H | 1 |
| Just, H | 1 |
| Lutz, JR | 2 |
| Allison, SB | 1 |
| Lui, HK | 1 |
| Lee, G | 1 |
| Dietrich, P | 1 |
| Low, RI | 1 |
| Mason, DT | 1 |
| Breithardt, G | 1 |
| Borggrefe, M | 1 |
| Yeh, HL | 1 |
| Seipel, L | 1 |
| Lee, CY | 1 |
| Teo, WS | 1 |
| Vanderhal, AL | 1 |
| Cocjin, J | 1 |
| Santulli, TV | 1 |
| Carlson, DE | 1 |
| Rosenthal, P | 1 |
| Randazzo, DN | 1 |
| Schweitzer, P | 1 |
| Stein, E | 1 |
| Banas, JS | 1 |
| Winters, SL | 1 |
| Wang, Z | 1 |
| Fermini, B | 1 |
| Goldberger, J | 1 |
| Helmy, I | 1 |
| Katzung, B | 1 |
| Leclercq, JF | 1 |
| Bizot, J | 1 |
| Attuel, P | 1 |
| Coumel, P | 1 |
| Midgley, DY | 1 |
| Harding, K | 1 |
| Fesslova, V | 1 |
| Villa, L | 1 |
| Nicolini, U | 1 |
| Kawabata, M | 1 |
| Hirao, K | 1 |
| Horikawa, T | 1 |
| Suzuki, K | 1 |
| Motokawa, K | 1 |
| Suzuki, F | 1 |
| Azegami, K | 1 |
| Hiejima, K | 1 |
| Vautier-Rit, S | 1 |
| Dufour, P | 1 |
| Vaksmann, G | 1 |
| Subtil, D | 1 |
| Vaast, P | 1 |
| Valat, AS | 1 |
| Dubos, JP | 1 |
| Puech, F | 1 |
| Kähler, C | 1 |
| Schleussner, E | 1 |
| Schneider, U | 1 |
| Seewald, HJ | 1 |
| Lüderitz, B | 1 |
| Jung, W | 1 |
| Manz, M | 1 |
| Tai, YT | 2 |
| Lau, CP | 2 |
| But, PP | 1 |
| Fong, PC | 1 |
| Li, JP | 1 |
| Perry, JC | 2 |
| Garson, A | 2 |
| Miller, LG | 1 |
| Jankovic, J | 1 |
| Lombardi, F | 1 |
| Finocchiaro, ML | 1 |
| Dalla Vecchia, L | 1 |
| Rech, R | 1 |
| Castelli, A | 1 |
| Pastine, J | 1 |
| Cappiello, E | 1 |
| Kulakowski, P | 1 |
| Gibson, S | 1 |
| Ward, J | 1 |
| Pratt, CM | 1 |
| Wagner, X | 1 |
| Jouglard, J | 1 |
| Moulin, M | 1 |
| Miller, AM | 1 |
| Petitjean, J | 1 |
| Pisapia, A | 1 |
| van Wijk, LM | 1 |
| Crijns, HJ | 2 |
| Kingma, HJ | 1 |
| van Gilst, WH | 1 |
| van Gelder, IC | 2 |
| Wesseling, H | 1 |
| Lie, KI | 2 |
| Jordaens, LJ | 1 |
| Tavernier, R | 1 |
| Vanmeerhaeghe, X | 1 |
| Robbens, E | 1 |
| Clement, DL | 1 |
| Frandsen, F | 1 |
| Pless, P | 1 |
| Mickley, H | 1 |
| Møller, M | 1 |
| Denes, P | 1 |
| Gillis, AM | 1 |
| Pawitan, Y | 1 |
| Kammerling, JM | 1 |
| Wilhelmsen, L | 1 |
| Salerno, DM | 1 |
| Frame, LH | 1 |
| Rhee, EK | 1 |
| Fei, H | 1 |
| Luchetti, W | 1 |
| Palitzsch, KD | 1 |
| Bode, H | 1 |
| Huck, K | 1 |
| Usadel, KH | 1 |
| Winslow, E | 1 |
| Campbell, JK | 1 |
| Barron, E | 1 |
| Marshall, RJ | 1 |
| Muir, AW | 1 |
| Allan, LD | 1 |
| Chita, SK | 1 |
| Sharland, GK | 1 |
| Maxwell, D | 1 |
| Priestley, K | 1 |
| Fish, FA | 1 |
| Gillette, PC | 3 |
| Benson, DW | 1 |
| Brugada, J | 1 |
| Boersma, L | 1 |
| Kirchhof, C | 1 |
| Allessie, M | 1 |
| Griffith, MJ | 1 |
| Linker, NJ | 1 |
| Garratt, CJ | 1 |
| Ward, DE | 3 |
| Ferrick, KJ | 1 |
| Power, M | 1 |
| Blakeman, BP | 1 |
| Wilber, D | 1 |
| Fauchier, JP | 2 |
| Cosnay, P | 2 |
| Babuty, B | 1 |
| Moquet, B | 2 |
| Rouesnel, P | 2 |
| Estepo, J | 1 |
| Houyel, L | 1 |
| Fournier, A | 1 |
| Davignon, A | 1 |
| Villain, E | 1 |
| Bonnet, D | 1 |
| Kachaner, J | 1 |
| Le Bidois, J | 1 |
| Cohen, L | 1 |
| Piéchaud, JF | 1 |
| Sidi, D | 1 |
| Schneeweiss, A | 1 |
| Herre, JM | 1 |
| Titus, C | 1 |
| Oeff, M | 1 |
| Eldar, M | 1 |
| Franz, MR | 1 |
| Griffin, JC | 1 |
| Scheinman, MM | 1 |
| Case, CL | 1 |
| D'Onofrio, A | 1 |
| Bourke, JP | 1 |
| Campbell, RW | 4 |
| Furlanello, F | 1 |
| Dal Forno, P | 1 |
| Cozzi, F | 1 |
| Bettini, R | 1 |
| Tubman, TR | 1 |
| Craig, B | 1 |
| Mulholland, HC | 1 |
| Köppel, C | 1 |
| Oberdisse, U | 1 |
| Heinemeyer, G | 1 |
| Muhiddin, KA | 1 |
| Turner, P | 1 |
| Hellestrand, K | 1 |
| Miura, D | 3 |
| Keefe, DL | 1 |
| Andresen, D | 1 |
| von Leitner, ER | 1 |
| Wegscheider, K | 1 |
| Theiss, A | 1 |
| Agena, H | 1 |
| Schröder, R | 1 |
| Nestico, PF | 1 |
| Morganroth, J | 3 |
| Myerburg, RJ | 1 |
| Kessler, KM | 1 |
| Cox, MM | 1 |
| Huikuri, H | 1 |
| Terracall, E | 1 |
| Interian, A | 1 |
| Fernandez, P | 1 |
| Castellanos, A | 1 |
| Polak, PE | 1 |
| Stewart, PA | 1 |
| Hess, J | 1 |
| McQuinn, RL | 1 |
| Smith, RT | 1 |
| Gothing, C | 1 |
| Fredell, P | 1 |
| Falk, RH | 1 |
| Nielsen, H | 1 |
| Pietersen, AH | 1 |
| Russell, GA | 1 |
| Martin, RP | 1 |
| Bleske, BE | 1 |
| Kluger, J | 2 |
| Fisher, J | 1 |
| Chow, MS | 2 |
| Filice, A | 1 |
| Attanasio, A | 1 |
| Capria, A | 1 |
| Piccolo, CG | 1 |
| Fabrizi, E | 1 |
| Ward, D | 1 |
| Garratt, C | 1 |
| Mikloweit, P | 1 |
| Bienmüller, H | 1 |
| Kunze, KP | 1 |
| Kuck, KH | 1 |
| Schlüter, M | 1 |
| Bleifeld, W | 1 |
| de Paola, AA | 1 |
| Horowitz, LN | 1 |
| Senior, S | 1 |
| Spielman, SR | 1 |
| Greenspan, AM | 1 |
| Kay, HR | 1 |
| Kou, WH | 1 |
| Nelson, SD | 1 |
| Lynch, JJ | 2 |
| Montgomery, DG | 2 |
| DiCarlo, L | 1 |
| Lucchesi, BR | 2 |
| Wren, C | 3 |
| Anastasiou-Nana, MI | 1 |
| Stewart, JR | 1 |
| Crevey, BJ | 1 |
| Yanowitz, FG | 1 |
| Johnson, TA | 1 |
| Winkelmann, BR | 1 |
| Leinberger, H | 1 |
| Cowan, JC | 1 |
| Holt, DW | 1 |
| Reid, DS | 1 |
| Berns, E | 2 |
| Rinkenberger, RL | 3 |
| Jeang, MK | 1 |
| Dougherty, AH | 3 |
| Jenkins, M | 1 |
| Naccarelli, GV | 3 |
| Tepper, D | 1 |
| Sacher, H | 1 |
| Schwarz, J | 1 |
| Taylor, EH | 1 |
| Kennedy, EE | 1 |
| Pappas, AA | 1 |
| Bauman, JL | 1 |
| Gallastegui, J | 1 |
| Tanenbaum, SR | 1 |
| Hariman, RJ | 1 |
| Klein, KL | 1 |
| Holloway, JD | 1 |
| Glasser, SP | 1 |
| Karl, M | 1 |
| Davies, DW | 1 |
| Mehta, D | 1 |
| Ward, DW | 1 |
| Kreeger, RW | 1 |
| Hammill, SC | 1 |
| DiCarlo, LA | 1 |
| Cohen-Solal, A | 1 |
| Juliard, JM | 1 |
| Jaeger, P | 1 |
| Farinotti, P | 1 |
| Dahan, M | 1 |
| Charlier, P | 1 |
| Boujon, B | 1 |
| Aumont, MC | 1 |
| Hunter, S | 1 |
| Sagie, A | 1 |
| Strasberg, B | 1 |
| Kusniec, J | 1 |
| Sclarovsky, S | 1 |
| Rechavia, E | 1 |
| Agmon, J | 1 |
| Capparelli, EV | 1 |
| Regnier, JC | 1 |
| Goedel-Meinen, L | 1 |
| Hofmann, M | 1 |
| Schmidt, G | 1 |
| Barthel, P | 1 |
| Baedeker, W | 1 |
| Blömer, H | 1 |
| Saoudi, N | 1 |
| Berland, J | 1 |
| Cribier, A | 1 |
| Letac, B | 1 |
| Zeigler, V | 1 |
| Ross, BA | 1 |
| Ewing, L | 1 |
| Wickers, F | 1 |
| Haissaguere, M | 1 |
| Palussiere, J | 1 |
| Cha, YM | 1 |
| Zhang, AP | 1 |
| Liu, L | 1 |
| Sun, JP | 1 |
| Huang, W | 1 |
| Gembruch, U | 1 |
| Hansmann, M | 1 |
| Bald, R | 1 |
| Hoffmann, A | 1 |
| Wenk, M | 1 |
| Follath, F | 1 |
| Wynn, J | 1 |
| Fingerhood, M | 1 |
| Keefe, D | 1 |
| Maza, S | 1 |
| Lal, R | 1 |
| Chapman, PD | 1 |
| Schechtman, KB | 1 |
| Troup, PJ | 1 |
| Ruffy, R | 1 |
| Bonnet, P | 1 |
| Scala, PJ | 1 |
| Demeyer, JF | 1 |
| Banitt, EH | 1 |
| Schmid, JR | 1 |
| Newmark, RA | 1 |
| Cheesman, M | 1 |
| Dancy, M | 1 |
| Jones, S | 1 |
| Shinebourne, EA | 1 |
| Flowers, D | 1 |
| O'Gallagher, D | 1 |
| Torres, V | 1 |
| Creamer, JE | 1 |
| Estes, M | 1 |
| Heine, DL | 1 |
| Garan, H | 1 |
| Ruskin, JN | 1 |
| Wehr, M | 1 |
| Noll, B | 1 |
| Krappe, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for flecainide and Tachycardia
| Article | Year |
|---|---|
Arrhythmias in Pregnancy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Humans; Pregnancy; Sotalol; Tachyca | 2022 |
Atrial Flutter in Pediatric Patients.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Flutter; Child; Child, Preschool; D | 2022 |
Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.
Topics: Anti-Arrhythmia Agents; Digoxin; Female; Fetal Diseases; Fetal Therapies; Flecainide; Humans; Pregna | 2017 |
Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Coronary Disease; Encaini | 1984 |
Flecainide induced atrial tachycardia with 1:1 ventricular conduction during exercise testing.
Topics: Aged; Atrial Function; Bundle-Branch Block; Diagnosis, Differential; Electrocardiography; Exercise T | 1994 |
Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing.
Topics: Arrhythmias, Cardiac; Child; Child, Preschool; Fetal Diseases; Flecainide; Humans; Infant; Tachycard | 1992 |
[Incessant idiopathic ventricular tachycardia in infants].
Topics: Amiodarone; Cardiomyopathies; Child, Preschool; Electrocardiography; Female; Flecainide; Follow-Up S | 1990 |
New antiarrhythmic drugs. II. Flecainide.
Topics: Child; Electrocardiography; Flecainide; Heart Ventricles; Humans; Tachycardia; Tachycardia, Supraven | 1990 |
Is drug treatment of tachyarrhythmias a science or a lottery?
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Flecainide; Humans; Propafenone; Tachycardia | 1990 |
The treatment of ventricular rhythm disturbances.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premat | 1986 |
New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
Topics: Administration, Oral; Amiodarone; Anilides; Anti-Arrhythmia Agents; Drug Interactions; Encainide; Fl | 1987 |
10 trials available for flecainide and Tachycardia
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Assessment of serum flecainide trough levels in patients with tachyarrhythmia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Dose-Response Re | 2005 |
Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Meth | 1983 |
Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trial | 1990 |
Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cross-Sectional Studies; Electric Countershock | 1991 |
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Disopyramid | 1990 |
Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Clinical Trials as Topic; Double- | 1985 |
[Comparative study of the anti-arrhythmia effect of flecainide acetate and prajmalium bitartrate in patients with tachycardiac ventricular rhythm disorders].
Topics: Adult; Aged; Ajmaline; Cardiac Complexes, Premature; Clinical Trials as Topic; Electrocardiography; | 1986 |
[Effect of class I anti-arrhythmia agents on the signal-averaged ECG].
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Clinical Trials as Topic; Coronary Disease; Disopyr | 1988 |
Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Electrocardi | 1988 |
133 other studies available for flecainide and Tachycardia
| Article | Year |
|---|---|
Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cesarean Section; Digoxin; Female; Fetal Diseases; Fle | 2022 |
Takotsubo cardiomyopathy triggered by a single dose of flecainide in patient with focal atrial tachycardia.
Topics: Adult; Catecholamines; Coronary Angiography; Echocardiography; Electrocardiography; Female; Flecaini | 2022 |
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Cardiomyopathies; Child; Female; Flecainide; Humans; Tachycardia; Tac | 2022 |
Wide Complex Tachycardia and Flecainide.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Tachycardia | 2022 |
Functional evaluation of the tachycardia patient-derived iPSC cardiomyocytes carrying a novel pathogenic SCN5A variant.
Topics: Arrhythmias, Cardiac; Flecainide; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; NAV1.5 | 2022 |
A Peculiar Wide Complex Tachycardia During Flecainide Treatment.
Topics: Flecainide; Humans; Tachycardia; Tachycardia, Paroxysmal | 2022 |
A very wide complex tachycardia.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Tachycardia | 2023 |
Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2023 |
How to differentiate second-degree atrioventricular block from extrasystoles in fetuses with a bigeminal ventricular rhythm.
Topics: Atrioventricular Block; Cardiac Complexes, Premature; Digoxin; Female; Fetus; Flecainide; Humans; Pr | 2020 |
Paroxysmal Atrial Fibrillation on Flecainide Therapy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Flecainide; Humans | 2020 |
Wide complex tachycardia in dialysis patients is not always hyperkalemia.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Humans; Hyperkalemia; Male; Middle Aged; Ta | 2022 |
Combined flecainide and sotalol therapy for multifocal atrial tachycardia in cardio-facio-cutaneous syndrome.
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Ectodermal Dysplasia; Electrocardiography; Facies | 2018 |
Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; Electrocardi | 2014 |
[Transplacental transport mechanisms of drugs for transplacental treatment of fetal tachyarrhythmia of MDCKII/MDCKII-BCRP cell line].
Topics: Animals; Biological Transport; Cell Membrane Permeability; Dogs; Female; Flecainide; Madin Darby Can | 2015 |
Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity.
Topics: Anti-Arrhythmia Agents; Bepridil; Bignoniaceae; Cytochrome P-450 CYP2D6; DNA, Complementary; Female; | 2015 |
Cardiac devices with class 1C antiarrhythmics: a potentially toxic combination.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershoc | 2015 |
Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations.
Topics: Anti-Arrhythmia Agents; Flecainide; Humans; Tachycardia; Tachycardia, Ventricular | 2016 |
Wide Complex Tachycardia in a Patient With a History of Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Fle | 2016 |
Flecainide vs digoxin for fetal supraventricular tachycardia: Comparison of 2 drug protocols.
Topics: Anti-Arrhythmia Agents; Digoxin; Fetal Diseases; Flecainide; Humans; Tachycardia; Tachycardia, Supra | 2016 |
Bullous fixed drug eruption caused by flecainide.
Topics: Aged; Anti-Arrhythmia Agents; Drug Eruptions; Flecainide; Humans; Male; Skin Diseases, Vesiculobullo | 2009 |
Life-threatening flecainide intoxication in a young child secondary to medication error.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Bradycardia; Cardiopulmonary Resuscitation; Child, Pre | 2009 |
Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Female; Flecainide; Heart Block; Humans | 2010 |
Management of persistent wide QRS in flecainide overdose with magnesium sulphate.
Topics: Adolescent; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Female; Flecainide; Humans; | 2010 |
Flecainide toxicity in a pediatric patient due to differences in pharmacy compounding.
Topics: Drug Compounding; Flecainide; Humans; Infant; Male; Pharmacy; Tachycardia | 2012 |
Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channels, L-Type; Dogs; El | 2003 |
What caused this wide-complex tachycardia?
Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Heart Conduction System; Humans; Male | 2003 |
Narrow QRS complex tachycardia with a high-frequency potential recorded near the His bundle: what is the mechanism?
Topics: Adult; Anti-Arrhythmia Agents; Bundle of His; Diagnosis, Differential; Electrocardiography; Flecaini | 2005 |
Successful treatment of tachycardia-induced cardiomyopathy with LVAD in a 12-year-old boy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Child; Flecainide; Heart Failure; Heart-Assist Devices; Hu | 2005 |
Flecainide treatment of fetal tachycardia and hydrops fetalis in a twin pregnancy.
Topics: Anti-Arrhythmia Agents; Echocardiography; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetali | 2006 |
Auto-intoxication with flecainide and quinapril: ECG-changes, symptoms and treatment.
Topics: Adolescent; Blood Pressure; Electrocardiography; Female; Flecainide; Humans; Quinapril; Tachycardia; | 2006 |
Ventricular tachycardia associated with flecainide.
Topics: Anti-Arrhythmia Agents; Female; Flecainide; Heart Ventricles; Humans; Middle Aged; Piperidines; Tach | 1982 |
New directions in antiarrhythmic drug therapy.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Benz | 1984 |
[Study of flecainide in the treatment of ventricular arrhythmia].
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; | 1983 |
Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1983 |
Retrograde gap in fast pathway conduction accentuated by the class I antiarrhythmic agent, flecainide.
Topics: Adult; Anti-Arrhythmia Agents; Atrioventricular Node; Bundle of His; Cardiac Pacing, Artificial; Ele | 1983 |
Sinusoidal ventricular tachycardia associated with flecainide acetate.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography; Female; Flecainide; | 1984 |
The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; | 1984 |
Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Electrocardiography; Flecainide; Heart Ventricl | 1983 |
Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrioventricular No | 1984 |
Flecainide toxicity.
Topics: Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Flecainide; Heart Ventricles; Humans; | 1984 |
Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death.
Topics: Aged; Anti-Arrhythmia Agents; Death, Sudden; Electrocardiography; Female; Flecainide; Hemodynamics; | 1984 |
Experience with electrophysiologically guided therapy of ventricular tachycardia with flecainide: summary of long-term follow-up.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; Follow-Up Studies; Hum | 1984 |
Effects of flecainide on ventricular function: clinical and experimental correlations.
Topics: Adult; Aged; Animals; Anti-Arrhythmia Agents; Cardiac Catheterization; Coronary Disease; Female; Fle | 1984 |
Oral flecainide for suppression of ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Dr | 1984 |
Flecainide-induced aggravation of ventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Female; Flecainide; Heart Rate; Humans; Middle Aged; Piperidines; Tachycardi | 1983 |
Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Blood Pressure; Bundle of His; Cardiac Pa | 1983 |
Flecainide-induced QT prolongation and ventricular tachycardia.
Topics: Coronary Disease; Electrocardiography; Flecainide; Humans; Male; Middle Aged; Piperidines; Tachycard | 1982 |
[Electrophysiological effects of flecainide on stimulus-inducible ventricular tachycardia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiograp | 1982 |
Electrocardiographic case. Irregular broad complex tachycardia. Wolff-Parkinson-White syndrome with atrial flutter-fibrillation.
Topics: Atrial Fibrillation; Atrial Flutter; Diagnosis, Differential; Electrocardiography; Flecainide; Human | 1994 |
Conjugated hyperbilirubinemia in a newborn infant after maternal (transplacental) treatment with flecainide acetate for fetal tachycardia and fetal hydrops.
Topics: Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Infant; Infant, Newborn; Jaundice, Neon | 1995 |
Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue.
Topics: Action Potentials; Animals; Atrial Function; Dogs; Electrophysiology; Flecainide; Heart; Heart Atria | 1993 |
Use-dependent properties of flecainide acetate in accessory atrioventricular pathways.
Topics: Adult; Confounding Factors, Epidemiologic; Electrocardiography; Electrophysiology; Female; Flecainid | 1994 |
Direct-current cardioversion of atrial tachyarrhythmias under oral flecainide therapy.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Chronic Disease; Electric Countershock; Electroc | 1997 |
The Mirror syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Pre-Ecla | 2000 |
Fetal hydrops due to a tachyarrhythmia progressing to organic pulmonary stenosis.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Echocardiography, Doppler; Female; Flecainide; Humans; Hydro | 2000 |
Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrocardiography; Electrophysio | 2001 |
[Fetal arrhythmias: diagnosis, prognosis, treatment; apropos of 33 cases].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bradycardia; Cardiac Complexes, Premature; Echocardiog | 2000 |
Prenatal diagnosis of the Wolf-Parkinson-White-syndrome by fetal magnetocardiography.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Fetal Diseases; Flecainide; Humans; Magn | 2001 |
[Combination anti-arrhythmic drug therapy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Drug Therapy, Combination; Electro | 1992 |
Bidirectional tachycardia induced by herbal aconite poisoning.
Topics: Aconitum; Anti-Arrhythmia Agents; Drugs, Chinese Herbal; Electric Countershock; Electrocardiography; | 1992 |
Persistent dystonia possibly induced by flecainide.
Topics: Bruxism; Dyskinesia, Drug-Induced; Dystonia; Flecainide; Heart Ventricles; Humans; Male; Mastication | 1992 |
Effects of mexiletine, propafenone and flecainide on signal-averaged electrocardiogram.
Topics: Adult; Aged; Aged, 80 and over; Electrocardiography, Ambulatory; Female; Flecainide; Heart Diseases; | 1992 |
Flecainide-related alterations in the signal-averaged electrocardiogram: similarity between patients with or without ventricular tachycardia.
Topics: Electrocardiography; Female; Flecainide; Heart Ventricles; Humans; Infusions, Intravenous; Male; Mid | 1992 |
Coadministration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk.
Topics: Adult; Cardiac Complexes, Premature; Drug Therapy, Combination; Female; Flecainide; Humans; Maternal | 1990 |
Flecainide: long-term effects in patients with sustained ventricular tachycardia or ventricular fibrillation.
Topics: Aged; Coronary Disease; Electric Stimulation; Electrocardiography, Ambulatory; Exercise Test; Female | 1990 |
Combination of flecainide and mexiletine for the treatment of ventricular tachyarrhythmias.
Topics: Aged; Cardiac Pacing, Artificial; Drug Therapy, Combination; Electrocardiography; Exercise Test; Fem | 1990 |
Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutte | 1990 |
Proarrhythmic and antiarrhythmic effects of flecainide on nonsustained reentry around the canine atrial tricuspid ring in vitro.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Conduction System; Humans; Tachycardia | 1991 |
[Successful multiple resuscitation in flecainide poisoning].
Topics: Adult; Electric Countershock; Electrocardiography; Female; Flecainide; Follow-Up Studies; Heart Arre | 1992 |
Effects of Org 7797 on early, late and inducible arrhythmias following coronary artery occlusion in rats and dogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Estrenes; Female; | 1991 |
Flecainide in the treatment of fetal tachycardias.
Topics: Cardiac Output, Low; Digoxin; Female; Fetal Death; Fetal Diseases; Flecainide; Humans; Pregnancy; Ta | 1991 |
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Death, Sudden; Encainide; Flecainide; | 1991 |
Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Flecainide; Heart Conduction System; In V | 1991 |
Profound exacerbation of neuromuscular weakness by flecainide.
Topics: Adult; Female; Flecainide; Heart Ventricles; Humans; Neuromuscular Diseases; Tachycardia | 1990 |
Surgical ablation for idiopathic ventricular tachycardia.
Topics: Adult; Bundle-Branch Block; Cryosurgery; Fibrosis; Flecainide; Humans; Hypertrophy; Male; Papillary | 1990 |
[Estimation of the long-term efficacy of anti-arrhythmia treatment with flecainide in ventricular tachycardia].
Topics: Adult; Aged; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiography, Ambulatory; Female; F | 1990 |
Successful treatment of chaotic atrial tachycardia with oral flecainide.
Topics: Administration, Oral; Electrocardiography; Flecainide; Heart Atria; Heart Failure; Humans; Infant; I | 1990 |
Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysi | 1990 |
Treatment of ventricular arrhythmias in children without structural heart disease with class IC agents as guided by invasive electrophysiology.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Child; Electroph | 1990 |
Left posterior fascicular tachycardia due to localized microreentry.
Topics: Adult; Electrocardiography; Electrophysiology; Flecainide; Humans; Male; Tachycardia | 1990 |
Arrhythmogenic effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Prop | 1990 |
Ventricular tachycardia associated with Coxsackie B4 virus infection.
Topics: Coxsackievirus Infections; Digoxin; Enterovirus B, Human; Female; Flecainide; Heart Rate; Humans; In | 1990 |
Clinical course and outcome in class IC antiarrhythmic overdose.
Topics: Ajmaline; Anti-Arrhythmia Agents; Bicarbonates; Bradycardia; Drug Overdose; Flecainide; Hemoperfusio | 1990 |
Flecainide: a new antiarrhythmic agent.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Dizziness; Electrophysiology; Flecainide; Hemody | 1986 |
Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; En | 1989 |
Complete atrioventricular dissociation and His bundle tachycardia in a newborn: problems in prenatal diagnosis and postnatal management.
Topics: Atrioventricular Node; Bundle of His; Cesarean Section; Diagnosis, Differential; Digoxin; Echocardio | 1989 |
Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Digoxin; Ech | 1989 |
Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Digoxin; Drug Therapy, Combination; Electrocardiography; Exercise Test; | 1989 |
[Repetitive ventricular tachycardia. A type of arrhythmia with good prognosis].
Topics: Adult; Female; Flecainide; Heart Ventricles; Humans; Prognosis; Tachycardia | 1989 |
Flecainide toxicity.
Topics: Animals; Flecainide; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Tachycardia | 1989 |
Acute effects of combination of IB and IC antiarrhythmics for the treatment of ventricular tachycardia.
Topics: Anilides; Anti-Arrhythmia Agents; Blood Pressure; Drug Therapy, Combination; Electric Stimulation; E | 1989 |
[Efficacy of flecainide in the treatment of ventricular tachycardia in the elderly. Dynamic electrocardiographic study].
Topics: Aged; Aged, 80 and over; Electrocardiography; Female; Flecainide; Heart Ventricles; Humans; Male; Mo | 1989 |
Cardiac arrhythmia suppression trial and flecainide.
Topics: Flecainide; Heart Arrest; Humans; Myocardial Infarction; Product Surveillance, Postmarketing; Tachyc | 1989 |
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].
Topics: Aged; Cholestasis, Intrahepatic; Drug Therapy, Combination; Enalapril; Female; Flecainide; Heart Fai | 1987 |
Effect of encainide and flecainide on chronic ectopic atrial tachycardia.
Topics: Adult; Anilides; Chronic Disease; Electrophysiology; Encainide; Female; Flecainide; Heart Atria; Hum | 1986 |
Influence of left ventricular dysfunction on flecainide therapy.
Topics: Adult; Aged; Female; Flecainide; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Stroke | 1987 |
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death.
Topics: Animals; Death, Sudden; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Electric Stimula | 1987 |
The response of paediatric arrhythmias to intravenous and oral flecainide.
Topics: Administration, Oral; Adolescent; Bundle of His; Child; Child, Preschool; Female; Flecainide; Heart | 1987 |
Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect.
Topics: Adult; Aged; Electrocardiography; Female; Flecainide; Heart Ventricles; Humans; Male; Middle Aged; P | 1987 |
Risk factors for the development of proarrhythmic events.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Hospitalization; Huma | 1987 |
Life-threatening flecainide toxicity. A pharmacodynamic approach.
Topics: Adult; Alcoholic Intoxication; Diazepam; Electrocardiography; Female; Flecainide; Heart Ventricles; | 1987 |
Flecainide--an intravenous infusion regimen.
Topics: Aged; Female; Flecainide; Humans; Infusions, Intravenous; Male; Middle Aged; Tachycardia; Ventricula | 1987 |
Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Heart Atria; Heart Ventricles; Humans; Tachyc | 1987 |
Chronic flecainide therapy selected by electrophysiology testing of intravenous flecainide.
Topics: Aged; Drug Administration Schedule; Electric Stimulation; Electrophysiology; Female; Flecainide; Hum | 1987 |
Determination of flecainide by gas chromatography-mass spectrometry.
Topics: Flecainide; Gas Chromatography-Mass Spectrometry; Humans; Indicators and Reagents; Tachycardia | 1987 |
Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine.
Topics: Aged; Electrocardiography; Flecainide; Humans; Lidocaine; Male; Tachycardia | 1987 |
His bundle tachycardia--arrhythmogenic and antiarrhythmic effects of therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bundle of His; Electrocardiography; Flecainide; Humans; Infant, | 1987 |
A paradoxical response to arrhythmia therapy.
Topics: Electrocardiography; Flecainide; Heart Ventricles; Humans; Male; Middle Aged; Tachycardia; Ventricul | 1987 |
Life-threatening flecainide toxicity.
Topics: Adult; Electric Countershock; Flecainide; Humans; Tachycardia | 1987 |
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Electrocardiography; Flecainide; | 1987 |
Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction.
Topics: Animals; Blood Pressure; Dogs; Electric Stimulation; Female; Flecainide; Heart Rate; Male; Myocardia | 1987 |
[Reduction of auricular fibrillation and tachycardia using intravenous flecainide].
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Flecainide; Heart Atria; Hemo | 1987 |
Maternal administration of flecainide to terminate and suppress fetal tachycardia.
Topics: Female; Fetal Diseases; Flecainide; Humans; Maternal-Fetal Exchange; Pregnancy; Tachycardia | 1988 |
Rapid suppression of flecainide-induced incessant ventricular tachycardia with high-dose intravenous amiodarone.
Topics: Amiodarone; Flecainide; Humans; Male; Middle Aged; Tachycardia | 1988 |
Clinical and electrophysiologic effects of flecainide in patients with refractory ventricular tachycardia.
Topics: Aged; Amiodarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrophysiology; Fe | 1988 |
[Bundle branch reentry tachycardia: a possible mechanism of flecainide proarrhythmia effect].
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Alcoholic; Drug Therapy, Combination; Electrocardio | 1988 |
Flecainide for supraventricular and ventricular arrhythmias in children and young adults.
Topics: Adolescent; Adult; Child; Child, Preschool; Echocardiography; Electrocardiography; Flecainide; Human | 1988 |
Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment.
Topics: Aged; Bundle-Branch Block; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Tachy | 1988 |
[QT prolongation and induction of torsades de pointe by flecainide. Apropos of a case].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans; Tachycardia | 1988 |
Flecainide acetate in dogs with ischemic tachyarrhythmia. An electrophysiologic study.
Topics: Animals; Dogs; Flecainide; Heart Conduction System; Myocardial Infarction; Tachycardia; Ventricular | 1988 |
Direct intrauterine fetal treatment of fetal tachyarrhythmia with severe hydrops fetalis by antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Female; Fetal Diseases; Flecainide; Humans; Hydrops Fetalis; Medigoxin; Preg | 1988 |
Treatment of resistant ventricular tachycardia with flecainide acetate. Flecainide Ventricular Tachycardia Study Group.
Topics: Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Piperidine | 1986 |
Exercise-induced ventricular tachycardia as a manifestation of flecainide toxicity.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; Heart Ventricles; Humans; Mi | 1986 |
Refractory ventricular tachycardia with flecainide.
Topics: Aged; Anti-Arrhythmia Agents; Flecainide; Heart Ventricles; Humans; Lidocaine; Male; Middle Aged; Pi | 1986 |
Flecainide in the treatment of nonsustained ventricular tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; Flecainide; Foll | 1986 |
[Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrop | 1985 |
Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzam ide acetate, and antiarrhythmic properties of the enantiomers.
Topics: Animals; Anti-Arrhythmia Agents; Chloroform; Dogs; Female; Flecainide; Magnetic Resonance Spectrosco | 1986 |
Effect of intravenous and oral flecainide on ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Dise | 1986 |
Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Child; Child, Preschool; Electrocardiography; Female; | 1986 |
Flecainide: long-term treatment using a reduced dosing schedule.
Topics: Anti-Arrhythmia Agents; Drug Administration Schedule; Electrocardiography; Female; Flecainide; Follo | 1985 |
Successful treatment of atrial tachycardias with flecainide acetate.
Topics: Adult; Anti-Arrhythmia Agents; Flecainide; Humans; Male; Middle Aged; Piperidines; Tachycardia | 1985 |
Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia.
Topics: Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; | 1985 |
Flecainide-induced aggravation of ventricular arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Humans | 1985 |